MEREO BIOPHARMA GROUP PLC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
MEREO BIOPHARMA GROUP PLC (MREO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of -$143.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-03-19
- MEREO BIOPHARMA GROUP PLC effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was -$143.00K.
- MEREO BIOPHARMA GROUP PLC effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was -$210.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | -$143.00K 10-K · filed 2026-03-19 |
| 2024-12-31 | -$210.00K 10-K · filed 2026-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |